Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
HOUSTON, May 31, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7 at 2:00 p.m. EDT in New York, NY.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors: Bellicum Pharmaceuticals Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles 646-513-3125 [email protected]
